Cheng-Jeng Tai |
------>authors3_c= ------>paper_class1=2 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol= ------>confirm_bywho=ncchang ------>insert_bywho=cjtai ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=2 ------>paper_class2Letter=None ------>page2= ------>medlineContent= ------>unit=E0109 ------>insert_date=20060424 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=-10000 ------>journal_name=2006 American Society of Clinical Oncology(ASCO), Atlanta, U.S.A. ------>paper_name=Cost-effective Treatment with Half Year of Trastuzumab and Chemotherapy as Adjuvant Treatment for Over Expression of Her2/Neu Breast Cancer Patients: Two Institutional Experiences in Taiwan ------>confirm_date=20060424 ------>tch_id=092092 ------>pmid=no found ------>page1= ------>fullAbstract=no found ------>tmu_sno=None ------>sno=13444 ------>authors2=Chin-Kwun Pan ------>authors3=Chi-Hsiung Wu ------>authors4=Ching-Syiang Chen ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Cheng-Jeng Tai ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=2 ------>updateTitle=no found ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2006 ------>submit_flag=None ------>publish_month=6 |